Citizens Commission on Human Rights International Releases Compilation Identifying 57 Regulatory Warnings on Psychotropic Drug Violence and Aggression Risks

Consumers should read drug labels—and ask prescribers to explain warnings about suicidal thoughts, aggression and homicidal ideation because a label alone does not ensure informed consent.

Los Angeles, CA, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Citizens Commission on Human Rights (CCHR), an international mental health industry watchdog, today released a compilation of international regulatory agency warnings and safety notices involving violence, aggression or hostility associated with some psychotropic drugs. The compilation identifies 57 warnings or safety notices since 2004, compared with five identified in 2004, and says 13 of those notices specifically reference homicidal ideation or thoughts of harming others. CCHR says the findings underscore the need for consumers to read psychotropic prescription drug labeling for warnings and adverse reactions involving suicide, aggression and homicidal ideation. The organization also says prescribing physicians should explain those risks, even when they are listed as rare, because a label alone does not ensure informed consent.

Psychiatrists must disclose what patients need to make informed decisions.

The call follows news reports of violent crimes in which some individuals were reported to have been taking, or withdrawing from, prescribed antidepressants, stimulants or other psychiatric drugs, with documented side effects of aggression, homicidal and suicidal ideation. CCHR says such reports underscore a broader consumer issue: patients should know what regulators and manufacturers disclose about these drugs and their prescribing physicians should ensure they are fully aware of potential risks.

CCHR’s decades-long campaign has drawn attention to reports of agitation, aggression, suicidal behavior and homicidal thoughts associated with some psychotropic drugs. U.S. and foreign regulators have subsequently required warnings or adverse-reaction information concerning such effects in the labeling of various psychiatric drugs.

Jan Eastgate, president of CCHR International, says: “A rare warning buried in a package insert is not the same as a doctor explaining the risk to a patient. Listing a side effect as ‘rare’ does not establish that the patient was told about it, understood it or agreed to take that risk. Meaningful informed consent requires meaningful disclosure and prescriber accountability.”

The question of a psychiatrist’s responsibility is also being debated in courtrooms and in the psychiatric profession. Psychiatric Times recently published “Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients’ Criminal Behavior?” Discussing a high-profile murder case in which the defense argued that psychiatric polypharmacy contributed to violent behavior, the journal said that “a good portion of the public and the media appear to support the defense theory” and that the litigation “places psychiatrists and other mental health providers under scrutiny.” The authors concluded that “psychiatry itself may end up on trial.”[1]

When prescribed drugs are alleged to have induced violent or otherwise criminal behavior, one legal doctrine is involuntary intoxication. Its applicability depends on the facts and governing law, including whether the drug was taken as prescribed and whether the person knew or reasonably could have known of the particular intoxicating or behavioral effect.

Eastgate says: “A judge allowing a jury to hear evidence about prescription drugs is not the same as a physician warning a patient before the first dose. The existence of a warning in drug labeling does not, by itself, establish that an individual patient was adequately informed. Psychiatrists must disclose what patients need to make informed decisions.”

The issue is not new. In a December 2005 article on psychopharmacology liability, Psychiatric Times discussed psychiatrists’ professional duties in the context of the FDA’s 2004 public health advisory on antidepressants. That advisory identified reports of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (severe restlessness), hypomania and mania in adults and children being treated with antidepressants. In October 2004, the FDA directed manufacturers to add a boxed warning concerning suicidality in children and adolescents; the warning was subsequently expanded to young adults.[2]

CCHR’s compilation of international regulatory agency warnings identifies 57 warnings or safety notices since 2004 involving violence, aggression or hostility, compared with five identified in 2004—a 1,040% increase. Thirteen of those notices specifically reference homicidal ideation or thoughts of harming others.

Drug labeling provides specific examples. Homicidal ideation was added to labeling for extended-release venlafaxine in 2005. In 2009, the FDA required a boxed neuropsychiatric warning for the antidepressant bupropion products, also used for smoking cessation, citing postmarketing reports that included hostility, agitation, aggression, psychosis, homicidal ideation and suicidal events. In 2023, the FDA required class-wide Central Nervous System stimulant labeling warning that “anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation” have been observed with stimulant abuse and/or misuse, including use other than as prescribed. Esketamine antidepressant nasal spray labeling instructs patients to seek medical attention for new or sudden changes in mood, behavior, thoughts or feelings, including acting aggressive, angry or violent. The antipsychotic aripiprazole lists homicidal ideation among rare adverse reactions reported in adults.

For CCHR, the central issue is what happens after such risks appear in official labeling. Printing a warning does not ensure that a patient has seen it, understood it, or discussed it with a physician.

That concern has also entered public policy. A 2026 Tennessee law requires toxicology testing for psychiatric and other drugs following specified violent incidents. CCHR has called for the law to be enacted in every state.

“Drug labeling now contains warnings and adverse-event information that consumers have a right to know about,” Eastgate says. “While not all individuals taking a prescription psychotropic drug will become violent or suicidal, they should read these warnings and ask questions before agreeing to treatment. Prescribers should explain potentially serious violent and suicidal adverse effects—including those considered rare—and document that the patient was given the information necessary to make an informed decision. A label alone does not ensure informed consent.” 

Ultimately, CCHR says the issue is not whether every patient taking a psychiatric drug will experience these reactions. The issue is whether patients are adequately informed when regulators and manufacturers have identified potentially serious behavioral adverse effects—and whether prescribers are held accountable for ensuring that patients are warned about those risks. Consumers should be able to weigh the risks, recognize warning signs should they emerge, and seek prompt medical advice about concerning changes.

Patients should not abruptly stop taking psychiatric drugs; any reduction or discontinuation should be undertaken with appropriate medical supervision.

CCHR, which was established in 1969 by the Church of Scientology and Dr. Thomas Szasz, professor of psychiatry, maintains that transparent disclosure of known risks—and prescriber accountability for providing that information—are fundamental to meaningful informed consent.

Sources:

[1] “Trial: Are Psychiatrists Responsible for Their Patients’ Criminal Behavior?,” Psychiatric Times, 27 Aug. 2026

[2] “Preventing and Reducing Professional Liability Risk Related to Psychopharmacology,” Psychiatric Times, 1 Dec. 2005

About Citizens Commission on Human Rights International

Citizens Commission on Human Rights (CCHR) is an international mental health industry watchdog, established by the Church of Scientology, which has helped enact more than 190 worldwide reforms that protect the public from abuse.

Press Inquiries

Amber Rauscher
media [at] cchr.org
323-467-4242
https://www.cchrint.org
6616 W. Sunset Blvd., Los Angeles, CA 90028